Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 18Colonic Neoplasms 4Rectal Neoplasms 2Neoplasm Metastasis 2Stomach Neoplasms 1Solid Tumor Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Metastatic Gastric Adenocarcinoma 1HER2 IHC3+ Advanced Colorectal Cancer 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Carcinoma 1Advanced/Metastatic Solid Tumors 1Advanced Gastric Cancer 1Adenocarcinoma 1

Interventions

Oxaliplatin 19pembrolizumab 13Fluorouracil 12Leucovorin 11Capecitabine 11Paclitaxel 10Gemcitabine 8Docetaxel 8zolbetuximab 6cemiplimab 6Cisplatin 6Albumin-Bound Paclitaxel 6durvalumab 5Ramucirumab 5Radiotherapy 5Irinotecan 4Cyclophosphamide 4130-nm albumin-bound paclitaxel 4trastuzumab deruxtecan 3tislelizumab 3lenvatinib 3enzalutamide 3darolutamide 3Trastuzumab 3Taxes 3S 1 (combination) 3Radiosurgery 3Pemetrexed 3Nivolumab 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × Trifluridine × 1 year × Clear all
NCT04879368 2025-07-17

INTEGRATEIIb

Australasian Gastro-Intestinal Trials Group

Phase 3 Active not recruiting
450 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡